138 related articles for article (PubMed ID: 38000294)
21. Bedaquiline susceptibility testing of Mycobacterium abscessus complex and Mycobacterium avium complex: A meta-analysis study.
Wang M; Men P; Zhang W; Wu J; Gu Y; Wang F; Huang H; Yu X; Duan H
J Glob Antimicrob Resist; 2024 Jun; 37():135-140. PubMed ID: 38561143
[TBL] [Abstract][Full Text] [Related]
22. Mutations in the MAB_2299c TetR Regulator Confer Cross-Resistance to Clofazimine and Bedaquiline in
Richard M; Gutiérrez AV; Viljoen A; Rodriguez-Rincon D; Roquet-Baneres F; Blaise M; Everall I; Parkhill J; Floto RA; Kremer L
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30323043
[TBL] [Abstract][Full Text] [Related]
23. A Mycobacterium tuberculosis cytochrome bd oxidase mutant is hypersensitive to bedaquiline.
Berney M; Hartman TE; Jacobs WR
mBio; 2014 Jul; 5(4):e01275-14. PubMed ID: 25028424
[TBL] [Abstract][Full Text] [Related]
24. Current Perspective of ATP Synthase Inhibitors in the Management of the Tuberculosis.
Divita KM; Khatik GL
Curr Top Med Chem; 2021; 21(18):1623-1643. PubMed ID: 34517802
[TBL] [Abstract][Full Text] [Related]
25. A bedaquiline/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria.
Ruth MM; Sangen JJN; Remmers K; Pennings LJ; Svensson E; Aarnoutse RE; Zweijpfenning SMH; Hoefsloot W; Kuipers S; Magis-Escurra C; Wertheim HFL; van Ingen J
J Antimicrob Chemother; 2019 Apr; 74(4):935-943. PubMed ID: 30649327
[TBL] [Abstract][Full Text] [Related]
26. Ionophoric effects of the antitubercular drug bedaquiline.
Hards K; McMillan DGG; Schurig-Briccio LA; Gennis RB; Lill H; Bald D; Cook GM
Proc Natl Acad Sci U S A; 2018 Jul; 115(28):7326-7331. PubMed ID: 29941569
[TBL] [Abstract][Full Text] [Related]
27. Delayed bactericidal response of Mycobacterium tuberculosis to bedaquiline involves remodelling of bacterial metabolism.
Koul A; Vranckx L; Dhar N; Göhlmann HW; Özdemir E; Neefs JM; Schulz M; Lu P; Mørtz E; McKinney JD; Andries K; Bald D
Nat Commun; 2014 Feb; 5():3369. PubMed ID: 24569628
[TBL] [Abstract][Full Text] [Related]
28. TBAJ-876 Retains Bedaquiline's Activity against Subunits c and ε of
Sarathy JP; Ragunathan P; Shin J; Cooper CB; Upton AM; Grüber G; Dick T
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31358589
[TBL] [Abstract][Full Text] [Related]
29. The NMR solution structure of Mycobacterium tuberculosis F-ATP synthase subunit ε provides new insight into energy coupling inside the rotary engine.
Joon S; Ragunathan P; Sundararaman L; Nartey W; Kundu S; Manimekalai MSS; Bogdanović N; Dick T; Grüber G
FEBS J; 2018 Mar; 285(6):1111-1128. PubMed ID: 29360236
[TBL] [Abstract][Full Text] [Related]
30. Bactericidal mode of action of bedaquiline.
Hards K; Robson JR; Berney M; Shaw L; Bald D; Koul A; Andries K; Cook GM
J Antimicrob Chemother; 2015 Jul; 70(7):2028-37. PubMed ID: 25754998
[TBL] [Abstract][Full Text] [Related]
31. In vitro activity of bedaquiline against slow-growing nontuberculous mycobacteria.
Martin A; Godino IT; Aguilar-Ayala DA; Mathys V; Lounis N; Villalobos HR
J Med Microbiol; 2019 Aug; 68(8):1137-1139. PubMed ID: 31210631
[TBL] [Abstract][Full Text] [Related]
32.
Martins O; Lee J; Kaushik A; Ammerman NC; Dooley KE; Nuermberger EL
Antimicrob Agents Chemother; 2021 Nov; 65(12):e0154521. PubMed ID: 34516254
[TBL] [Abstract][Full Text] [Related]
33. Emergence of nontuberculous mycobacteria infections during bedaquiline-containing regimens in multidrug-resistant tuberculosis patients.
Gao J; Pei Y; Yan X; Shi G; Li T; Gao M; Liu Y; Wang Y; Shu W; Li L; Pang Y
Int J Infect Dis; 2020 Nov; 100():196-198. PubMed ID: 32890726
[TBL] [Abstract][Full Text] [Related]
34. Validation of bedaquiline drug-susceptibility testing by BACTEC MGIT 960 system for
Sivaramakrishnan G; Subramanyam B; Kumar MP; Golla R; Tripathy SP; Mondal R
Int J Mycobacteriol; 2019; 8(4):329-332. PubMed ID: 31793501
[TBL] [Abstract][Full Text] [Related]
35. A tale of two inhibitors: diarylquinolines and squaramides.
Chen J; Ekiert DC
EMBO J; 2023 Aug; 42(15):e114912. PubMed ID: 37435707
[TBL] [Abstract][Full Text] [Related]
36. Insights into the Physiology and Metabolism of a Mycobacterial Cell in an Energy-Compromised State.
Patil V; Jain V
J Bacteriol; 2019 Oct; 201(19):. PubMed ID: 31285242
[No Abstract] [Full Text] [Related]
37. Bedaquiline Targets the ε Subunit of Mycobacterial F-ATP Synthase.
Kundu S; Biukovic G; Grüber G; Dick T
Antimicrob Agents Chemother; 2016 Nov; 60(11):6977-6979. PubMed ID: 27620476
[TBL] [Abstract][Full Text] [Related]
38. Mining of the Novel Virulent ATP-Binding Cassette Importers in
Xue S; Ma J; Li SS; Fan S; Cai Y; Li J; Fu X; Deng Z; Sun QH; Sun YC; Ma W
Microb Drug Resist; 2022 Dec; 28(12):1057-1064. PubMed ID: 36534487
[No Abstract] [Full Text] [Related]
39. An update on ATP synthase inhibitors: A unique target for drug development in M. tuberculosis.
Kelam LM; Wani MA; Dhaked DK
Prog Biophys Mol Biol; 2023; 180-181():87-104. PubMed ID: 37105260
[TBL] [Abstract][Full Text] [Related]
40. Differential
Lee J; Ammerman N; Agarwal A; Naji M; Li SY; Nuermberger E
Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33168614
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
